Back to Journals » Patient Preference and Adherence » Volume 9

Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b

Authors Weller I, Saake A, Schreiner T, Vogelreuter J, Petroff N, Koch C

Received 1 April 2015

Accepted for publication 29 May 2015

Published 7 July 2015 Volume 2015:9 Pages 951—959

DOI https://doi.org/10.2147/PPA.S85917

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Johnny Chen

Ivonne Weller,1 Anna Saake,1 Thomas Schreiner,1 Julika Vogelreuter,1 Nicolas Petroff2

1
Bayer Vital GmbH, Leverkusen, Germany; 2Vitartis Medizin-Service GmbH, Göttingen, Germany

Purpose: Multiple sclerosis (MS) is a chronic demyelinating, degenerative disease requiring long-term treatment. Patient adherence to treatment may be challenging in such scenarios, especially since treatment often involves self-injection, for example, with interferon beta-1b during therapy. BETACONNECT™ is a novel electronic autoinjector for patient support in interferon beta-1b administration. The purpose of this survey was to assess patient satisfaction with the BETACONNECT™ device and its features.
Patients and methods: A total of 2,299 MS patients using the BETACONNECT™ device were asked to participate in a survey in October 2014. All of these candidates participated in the BETAPLUS® program and had provided written informed consent. The participants were asked to answer 13 device-related questions.
Results: Of these candidates, 1,365 replied to the questionnaire, with more than 60% of the participants being 40–59 years of age. Among them, 69% were women and 21% were men (10% not specified). Approximately half of the participants received treatment with interferon beta-1b for more than 5 years. Most participants (85%) had used self-injection devices before, with 59% previously using BETACOMFORT®, 23% using BETAJECT® Comfort, and 3% using BETAJECT® Lite, while less than 4% manually injected interferon beta-1b. The majority of the participants had received the BETACONNECT™ device from a BETAPLUS® nurse (87%) and 48% had already used the device for more than 2 months (49% for 2 months or less). Among the participants, more than 90% evaluated the BETACONNECT™ device as “very helpful” or “helpful” in supporting their interferon beta-1b therapy with only marginal sex differences. Features that were rated “very important” by more than half of the participants included adjustability of injection speed and depth, contact sensor for avoidance of unintentional release, optical and acoustic signals, and rechargeable battery.
Conclusion: The vast majority of patients rated the BETACONNECT™ device as very helpful or helpful for their treatment with interferon beta-1b, and many considered most features as “very important”. In conclusion, usage of the BETACONNECT™ autoinjector may facilitate interferon beta-1b therapy and support adherence to long-term therapeutic regimen.

Keywords: relapsing–remitting multiple sclerosis, RRMS, immunomodulatory therapy, electronic autoinjector, patient survey

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Autoinjector preference among patients with multiple sclerosis: results from a national survey

Limmroth V, Reischl J, Mann B, Morosov X, Kokoschka A, Weller I, Schreiner T

Patient Preference and Adherence 2017, 11:1325-1334

Published Date: 3 August 2017

Readers of this article also read:

Polyetherimide-grafted Fe3O4@SiO2 nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging

Li T, Shen X, Chen Y, Zhang C, Yan J, Yang H, Wu C, Zeng H, Liu Y

International Journal of Nanomedicine 2015, 10:4279-4291

Published Date: 2 July 2015

Quetiapine for acute bipolar depression: a systematic review and meta-analysis

Suttajit S, Srisurapanont M, Maneeton N, Maneeton B

Drug Design, Development and Therapy 2014, 8:827-838

Published Date: 25 June 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010